Key Dates

Related Announcements

PAR-22-114 - Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform the applicant community of a change/clarification to the Funding Opportunity Announcement (FOA) PAR-22-114, Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional).

The following section of PAR-22-114 has been amended to include the sentence in bold italics:

:

Part 2. Content and Form Application Submission, Section IV. Application and Submission Information

2. Content and Form of Application Submission

Instructions for Electronic Application Submission through Grants.gov

Use the “Apply” button(s) in Part I of this announcement to access the application forms package posted at Grants.gov. If presented with more than one form package, use the Competition ID and Competition Titles provided to determine the most appropriate application forms package for your situation.

Prepare applications using the SF424 (R&R) forms associated with the chosen package. Please note that some forms marked optional in the application package are required for submission of applications for this announcement. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate required and optional forms, with the following additional guidance:

• • SF424 R&R Cover form: Select “Revision” in the “Type of Application” field.
  • R&R Other Project Information form: If applicable, attach PDF documents in the “Other Attachments” field indicating that the proposed research experience was approved by the Institutional Animal Care and Use Committee (IACUC) or human subjects Institutional Review Board (IRB) at the recipient institution. Name the documents “IACUC Documentation.pdf” and/or “IRB Documentation.pdf”. Adherence to the NIH policy for including women and minorities in clinical studies must also be ensured, if additional human subjects’ involvement is planned for the supplement.
  • Project/Performance Site Location(s) form: Include the primary site where the proposed supplement activities will be performed. If a portion of the proposed supplement activities will be performed at any other site(s), identify the locations in the fields provided.
  • Sr/Key Person Profile (Expanded) form: List the PD/PI as the first person (regardless of their role on the supplement activities). List any other Senior/Key Personnel who are being added through this supplement, or for whom additional funds are being requested through this supplement; include a biographical sketch for each. Supplement funds may not be used for PI salary support during the regular or extended period of the grant.
  • Budget forms (e.g., R&R Budget, PHS 398 Training Budget): Only include funds requested for the additional supplement activities.
  • Research Plan form (e.g., PHS 398 Research Plan form, PHS 398 Research Training Program Plan): At a minimum, the Research Strategy section should be completed and must include a summary or abstract of the funded parent award or project. Other sections should also be included if they are being changed by the proposed supplement activities.
  • PHS Human Subjects and Clinical Trials Information: When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide.

All other aspects of PAR-22-114 remain unchanged.

Inquiries

Please direct all inquiries to:

Maria Jamela R. Revilleza, PhD, MSc
National Cancer Institute (NCI)
Telephone: 240-620-0616
Email: mariajamela.revilleza@nih.gov